IDEXX Laboratories, Inc., today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market and sell SURPASS™ (1% diclofenac sodium) Topical Anti-Inflammatory Cream, a new treatment for horses with pain and lameness due to osteoarthritis. SURPASS topical cream represents the first equine pharmaceutical use of a topical liposomal formulation of the FDA-approved nonsteroidal anti-inflammatory drug, diclofenac. The product is labeled as a veterinary-only prescription medication to be used under the supervision of a licensed, practicing veterinarian.

“Used in a comprehensive pain management program, SURPASS topical cream offers localized pain relief without many of the side effects seen with systemic products,” commented IDEXX President and CEO, Jonathan Ayers. “SURPASS is manufactured to exacting standards for incorporation of the powerful pain reliever, diclofenac, in a proprietary liposomal formulation. This means practitioners can count on consistency in every tube.”

Label information for the product follows. Please check back for updates on the medication.

Product Information:

SURPASS™ (1% diclofenac sodium)
Topical Anti-Inflammatory Cream for Use in Horses
Brief Summary

Please consult the full package insert for more information.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description: SURPASS™ topical cream contains 1% diclofenac sodium in a liposomal formulation.

Indications: SURPASS topical cream is indicated for the control of pain and inflammation associated with osteoarthritis (OA) in tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal (hock, knee, fetlock and pastern) joints in horses.